Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...3334353637383940414243...858859»
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal:  Blinatumomab in the Therapy of Acute B-Lymphoid Leukemia. (Pubmed Central) -  Sep 11, 2024   
    These therapeutic successes have led to FDA approval for refractory/relapsed and MRD-positive B-ALL patients. Furthermore, recent studies in newly diagnosed B-ALL patients have led in Philadelphia chromosome-positive patients to the development of chemotherapy-free regimens based on tyrosine kinase inhibitors plus Blinatumomab and in Philadelphia chromosome-negative patients to improvement in outcomes using chemotherapy regimens that have incorporated Blinatumomab in the consolidation phase of treatment.
  • ||||||||||  Prolia (denosumab) / Amgen
    Clinical, Retrospective data, Review, Journal:  Impact of anti-fracture medications on bone material and strength properties: a systematic review and meta-analysis. (Pubmed Central) -  Sep 11, 2024   
    Additionally, anti-resorptives (bisphosphonates and denosumab) significantly increased crystallinity [SDM 0.387], mineral-matrix ratio [SDM 0.771], microhardness [SDM 0.858], and contact hardness [SDM 0.952] of cortical bone...In strontium ranelate-treated patients, there was no difference in BMPs compared to placebo. Collectively, our study suggests that AFMs improve bone quality, which explains their anti-fracture ability that is not fully accounted for by increased BMD in osteoporosis patients.
  • ||||||||||  ivabradine / Generic mfg., milrinone / Generic mfg.
    Journal:  Ivabradine and Milrinone-Bridge to Recovery in New HFrEF With Low-Output Heart Failure. (Pubmed Central) -  Sep 11, 2024   
    Ivabradine and/or home milrinone were used during their tenuous hemodynamic period as a bridge to optimize guideline-directed medical therapy (GDMT), device therapy, and eventual reverse remodeling. Evidence of structural heart improvement continued far beyond 1 year.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB, Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
    ASSOCIATION OF MONOCLONAL ANTIBODY TREATMENT WITH THE DEVELOPMENT OF STRESS CARDIOMYOPATHY (Convention Center Exhibit Hall: Poster Area 1) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6320;    
    The FRAME study found similar incidence of cardiovascular events with romosozumab-denosumab compared to placebo-denosumab [1]...An analysis of the reSURFACE 1 and 2 trials found limited cardiovascular events with tildrakizumab, similar to placebo [3]... This case highlights a potential association between monoclonal antibodies and stress cardiomyopathy, however, the exact mechanism is uncertain emphasizing the need for further research.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    PK/PD data, Preclinical, Journal:  Pharmacokinetic interaction between regorafenib and atorvastatin in rats. (Pubmed Central) -  Sep 10, 2024   
    This animal model study showed a significant pharmacokinetic interaction between regorafenib and atorvastatin. While this interaction may be clinically significant, this needs to be confirmed in clinical trials involving cancer patients.
  • ||||||||||  Journal:  Mechanistic modeling of cell viability assays with in silico lineage tracing. (Pubmed Central) -  Sep 10, 2024   
    Variations in mother cells prior to drug treatment all impinging on ERK pathway activity are associated with the rapidly dividing phenotype and trametinib resistance. This work lays a foundation for the application of mechanistic modeling to large-scale cell viability assay datasets and better understanding determinants of cellular heterogeneity in drug response.
  • ||||||||||  Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
    Clinical, Review, Journal:  Use and effectiveness of PCSK-9 inhibitors in heart diseases: A review. (Pubmed Central) -  Sep 10, 2024   
    This review identified only a few clinical trials on PCSK-9 inhibitors in heart disease patients. Therefore, it is recommended to conduct more randomized controlled clinical trials on PCSK-9 inhibitors in this patient population.
  • ||||||||||  Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
    Journal, Real-world evidence, Real-world:  Efficacy and tolerability of PCSK9 inhibitors in real-world clinical practice. (Pubmed Central) -  Sep 9, 2024   
    The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with familial hypercholesterolaemia and high CV risk in the UK. We reviewed the records of patients at a large health board in Scotland, who were prescribed these agents, to determine their real- world efficacy and tolerability in routine clinical care.
  • ||||||||||  AMG 193 / Amgen
    Phase 1b Study of AMG 193, An MTA-Cooperative PRMT5i, Alone and in Combination with Other Therapies in MTAP-deleted NSCLC (Exhibit Hall) -  Sep 8, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2887;    
    Subprotocol B (N ~ 94) will evaluate AMG 193 plus sotorasib in MTAP -deleted and KRAS G12C-mutated NSCLC...Patients will be required to have PD-L1-positive tumors in subprotocol A arm C, KRAS G12C-mutated tumors in subprotocol B, and active brain metastasis in subprotocol C. AMG 193 will be administered daily continuously. The study is expected to start recruitment in April 2024.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Long-Term Outcomes with Sotorasib in KRAS G12c-Mutated Advanced NSCLC from the Global Expanded Access Program (EAP) Study-436 (Exhibit Hall) -  Sep 8, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2884;    
    50% 35 8.4 (6.0-12.7) 5.0 (3.4-6.5) Unknown/missing 10 11.8 (0.8-NE) 3.6 (0.8-24.3) *rwPFS was estimated based on time from start of sotorasib to end of protocol due to disease progression or death, any death before new anticancer therapy, or end of commercial sotorasib, whichever occurred earlier. CI, confidence interval; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group Performance Status; PD-L1, programmed death-ligand 1.
  • ||||||||||  Review, Journal:  Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review. (Pubmed Central) -  Sep 8, 2024   
    CI, confidence interval; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group Performance Status; PD-L1, programmed death-ligand 1. This systematic review provides robust evidence regarding treatment options for individuals with psoriasis and MD, emphasizing the potential benefits of specific drugs in managing both conditions concurrently.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal, Real-world evidence, Real-world:  Real-world data on tezepelumab in patients with severe asthma in Germany. (Pubmed Central) -  Sep 8, 2024   
    In this real-life cohort, including a large proportion of patients with history of previous biologic use and encompassing various subgroups, the majority responded to tezepelumab. Our data further suggest a steroid-sparing effect of tezepelumab.
  • ||||||||||  Review, Journal, Metastases:  Third-Line Treatment and Beyond in Metastatic Colorectal Cancer: What Do We Have and What Can We Expect? (Pubmed Central) -  Sep 7, 2024   
    Anti-EGFR rechallenge, anti-HER2 targeted therapies or the promising results of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC), are some of the available options thay may modify what is presumably third-line colorectal treatment. Hereby, we present the evidence of the different treatment options in third-line colorectal cancer and beyond, as well as the possibilities of sequencing them.
  • ||||||||||  SB202190 / Amgen
    Journal:  Bacterial peptidoglycan signalling in microglia: Activation by MDP via the NF-?B/MAPK pathway. (Pubmed Central) -  Sep 7, 2024   
    These findings underscore the significance of different MDP levels in shaping microglial function in the CNS and indicate MDP as a potential mediator for early inflammatory processes in the brain. It also positions microglia as an important target in the gut microbiota-brain-axis pathway through PGN signalling.
  • ||||||||||  ivabradine / Generic mfg.
    Review, Journal:  Ivabradine approved and other uses in clinical practice: a systematic review. (Pubmed Central) -  Sep 6, 2024   
    Promising results have been reported on the efficacy of IVA in controlling HR, especially in patients with inappropriate sinus tachycardia or POTS. Due to the unique mechanism of action, IVA has the potential to be used more frequently in future clinical practice.
  • ||||||||||  cyclophosphamide / Generic mfg.
    Review, Journal, Oncolytic virus, IO biomarker:  Synergistic effects of herpes oncolytic virus and cyclophosphamide for recurrent malignant glioma: a narrative review. (Pubmed Central) -  Sep 6, 2024   
    Preclinical and clinical studies demonstrate the safety and efficacy of oHSVs, with T-Vec being FDA-approved...CPA's immunomodulatory effects, suppressing regulatory T cells, improve oHSV efficiency. While obstacles remain, this synergistic approach offers hope for improved outcomes, necessitating further research and clinical validation.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal, Checkpoint inhibition:  Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review. (Pubmed Central) -  Sep 5, 2024   
    As a neoadjuvant medication and/or to control tumor progression, zoledronic acid may be the more economic option especially for patients in developing countries. Although response rates to ICIs for BM are poor, patients treated with ICI plus denosumab for bone metastases with impending fractures from NSCLC and melanoma are likely to avoid surgery to prevent fractures.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Rituxan (rituximab) / Roche
    Journal:  Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia. (Pubmed Central) -  Sep 5, 2024   
    The treatment of BCP-ALL in adults has been transformed with the approval of inotuzumab ozogamicin (anti-CD22 antibody drug conjugate), blinatumomab (CD3/CD19 bispecific antibody construct), and CAR T-cells for relapsed or refractory disease, and of blinatumomab for measurable residual disease (MRD)-positive remission...Blinatumomab has also been shown in a randomized trial to provide a survival benefit in patients with MRD-negative first remission when added to chemotherapy which recently led to its additional FDA approval for use in consolidation. In this review, we highlight the evolution of chemoimmunotherapy-based treatment approaches in the management of treatment-na
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Three cases of uncommon medication-associated osteonecrosis of temporal bone. (Pubmed Central) -  Sep 5, 2024   
    She had a history of osteoporosis treated with denosumab and risedronic acid...He had a history of osteoporosis treated with alendronic acid and zoledronic acid...He had a history of chronic myelogenous leukemia treated with a tyrosine-kinase inhibitor, imatinib...Anti-resorptive agents and/or tyrosine kinase inhibitors may lead to dysregulation of bone remodeling and result in rare cases of temporal bone osteonecrosis. When a local debridement and antibiotic therapy fail, definitive surgical excision of necrotic bone with subsequent reconstruction of the EAC may offer patients a possible resolution in symptoms.
  • ||||||||||  Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
    Review, Journal:  Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers. (Pubmed Central) -  Sep 5, 2024   
    Structure-activity relationship (SAR) studies have been instrumental in optimizing the binding affinity, selectivity, and pharmacokinetic properties of these inhibitors, leading to the development of promising therapeutic agents like Sotorasib and Adagrasib. This review provides an overview of the KRAS pathway, KRAS binding sites, strategies for direct and indirect inhibition using small molecules, and SAR based on the co-crystal structures of inhibitors with KRAS mutants which is expected to offer new hope for patients with KRAS-driven cancers through the development of new KRAS-targeted drugs.